Portal de Periódicos da CAPES

Management of PD-1/PD-L1 Blockade Immune-Related Skin Toxicities: Perspectives and Issues

2021; Future Medicine; Volume: 13; Issue: 10 Linguagem: Inglês

10.2217/imt-2021-0071

1750-7448

Martina Ferranti, Giulia Tadiotto Cicogna, Francesco Messina, Mauro Alaibac,

Chemotherapy-related skin toxicity

ImmunotherapyVol. 13, No. 10 EditorialManagement of PD-1/PD-L1 blockade immune-related skin toxicities: perspectives and issuesMartina Ferranti, Giulia Tadiotto Cicogna, Francesco Messina & Mauro AlaibacMartina Ferranti https://orcid.org/0000-0002-0216-5226Department of Medicine-DIMED, Unit of Dermatology, University of Padova, Padova, Italy, Giulia Tadiotto Cicogna https://orcid.org/0000-0003-4443-6204Department of Medicine-DIMED, Unit of Dermatology, University of Padova, Padova, Italy, Francesco Messina https://orcid.org/0000-0002-7959-5881Department of Medicine-DIMED, Unit of Dermatology, University of Padova, Padova, Italy & Mauro Alaibac *Author for correspondence: Tel.: +39 049 821 2901; E-mail Address: mauro.alaibac@unipd.ithttps://orcid.org/0000-0001-6524-4848Department of Medicine-DIMED, Unit of Dermatology, University of Padova, Padova, ItalyPublished Online:6 May 2021https://doi.org/10.2217/imt-2021-0071AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: anti-PD1 inhibitorsanti-PDL1 inhibitorsimmune-checkpoint inhibitorsimmune-related adverse eventsimmunotherapyrechallengeskin toxicitiesReferences1. Barber FD. Adverse events of oncologic immunotherapy and their management. Asia Pac. J. Oncol. Nurs. 6(3), 212–226 (2019).Crossref, Medline, Google Scholar2. Sadreddini S, Baradaran B, Aghebati-Maleki A et al. Immune checkpoint blockade opens a new way to cancer immunotherapy. J. Cell. Physiol. 234(6), 8541–8549 (2019).Crossref, Medline, CAS, Google Scholar3. Puzanov I, Diab A, Abdallah K et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J. Immunother. Cancer 5(1), 95 (2017).Crossref, Medline, CAS, Google Scholar4. Martins F, Sofiya L, Sykiotis GP et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat. Rev. Clin. Oncol. 16(9), 563–580 (2019).Crossref, Medline, CAS, Google Scholar5. Haanen JBAG, Carbonnel F, Robert C et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 28(Suppl. 4), iv119–iv142 (2017).Crossref, Medline, CAS, Google Scholar6. Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am. J. Clin. Dermatol. 19(3), 345–361 (2018).Crossref, Medline, Google Scholar7. Bonigen J, Raynaud-Donzel C, Hureaux J et al. Anti-PD1-induced psoriasis: a study of 21 patients. J. Eur. Acad. Dermatol. Venereol. 31(5), e254–e257 (2017).Crossref, Medline, CAS, Google Scholar8. Law-Ping-Man S, Martin A, Briens E, Tisseau L, Safa G. Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced lung cancer. Rheumatology (Oxford) 55(11), 2087–2089 (2016).Crossref, Medline, Google Scholar9. Ruiz-Bañobre J, Pérez-Pampín E, García-González J et al. Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature. Lung Cancer 108, 217–221 (2017).Crossref, Medline, Google Scholar10. Tanaka R, Okiyama N, Okune M et al. Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-α is a biomarker of nivolumab recativity. J. Dermatol. Sci. 86(1), 71–73 (2017).Crossref, Medline, CAS, Google Scholar11. Rofe O, Bar-Sela G, Keidar Z, Sezin T, Sadik CD, Bergman R. Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression. Clin. Exp. Dermatol. 42(3), 309–312 (2017).Crossref, Medline, CAS, Google Scholar12. Sowerby L, Dewan AK, Granter S, Gandhi L, LeBoeuf NR. Rituximab treatment of nivolumab-induced bullous pemphigoid. JAMA Dermatol. 153(6), 603–605 (2017).Crossref, Medline, Google Scholar13. Damsky W, Kole L, Tomayko MM. Development of bullous pemphigoid during nivolumab therapy. JAAD Case Rep. 2(6), 442–444 (2016).Crossref, Medline, Google Scholar14. Mihailescu ML, Brockstein BE, Desai N, Waldinger J. Successful reintroduction and continuation of nivolumab in a patient with immune checkpoint inhibitor-induced bullous pemphigoid. Curr. Probl. Cancer Case Rep. 2, 100031 (2020).Google Scholar15. Kremer N, Snast I, Cohen ES et al. Rituximab and omalizumab for the treatment of bullous pemphigoid: a systematic review of the literature. Am. J. Clin. Dermatol. 20(2), 209–216 (2019).Crossref, Medline, Google Scholar16. Brahmer JR, Lacchetti C, Schneider BJ et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. 36(17), 1714–1768 (2018).Crossref, Medline, CAS, Google Scholar17. Bowyer S, Prithviraj P, Lorigan P et al. Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. Br. J. Cancer 114(10), 1084–1089 (2016).Crossref, Medline, CAS, Google Scholar18. Santini FC, Rizvi H, Plodkowski AJ et al. Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC. Cancer Immunol. Res. 6(9), 1093–1099 (2018).Crossref, Medline, CAS, Google Scholar19. Ghosn J, Vicino A, Michielin O, Coukos G, Kuntzer T, Obeid M. A severe case of neuro-Sjögren's syndrome induced by pembrolizumab. J. Immunother. Cancer 6(1), 110 (2018).Crossref, Medline, Google Scholar20. Leaf RK, Ferreri C, Rangachari D et al. Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. Am. J. Hematol. 94(5), 563–574 (2019).Crossref, Medline, CAS, Google Scholar21. Rothenberg ME, Klion AD, Roufosse FE et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N. Engl. J. Med. 358(12), 1215–1228 (2008).Crossref, Medline, CAS, Google Scholar22. Kuang FL, Legrand F, Makiya M et al. Benralizumab for PDGFRA-negative hypereosinophilic syndrome. N. Engl. J. Med. 380(14), 1336–1346 (2019).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetails Vol. 13, No. 10 Follow us on social media for the latest updates Metrics Downloaded 139 times History Received 26 March 2020 Accepted 19 April 2021 Published online 6 May 2021 Published in print July 2021 Information© 2021 Future Medicine LtdKeywordsanti-PD1 inhibitorsanti-PDL1 inhibitorsimmune-checkpoint inhibitorsimmune-related adverse eventsimmunotherapyrechallengeskin toxicitiesAuthor contributionsM Ferranti, GT Cicogna and F Messina contributed to the conceptualization of manuscript, literature search from database, writing and first draft of manuscript. M Alaibac was responsible for content modification, the scientific advice and critical review before final resubmission.Financial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants, or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download